Biological Products Indications Expected Expiry date
Adalimuzumab (Humara) Rhematoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease 2018(EU)
2016(US)
Bevacizumab (Avastin) Metastatic colorectal cancer, HER2 negative breast cancer 2022 (EU)
2019 (US)
Cetuximab( Erbitux) EGFR expressing metastatic colorectal cancer, squamous cell carcinoma of the head and neck 2014(EU)
2016(US)
Etanercept (Enbrel) Rheumatoid arthritis,ankylosing spondylitis, plaque psoriasis 2015(EU)
2013 (US)
Infliximab (Remicad) Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis 2014(EU)
2018(US)
Palivizumab (Synagis) Respiratory disease caused by respiratory syncytial virus 2015(EU)
2015(US)
Retuximab(Rituxan) CD-20-positive non-Hodgkinslymphoma,chronic lymphocytic leukemia, rheumatoid arthritis 2013(EU)
2018(US)
Trastuzumab (Herceptin) HER2-positive breast cancer, metastatic breast cancer that overexpresses HER2 2014 (EU)
2019(US)
Table 3:  Expected patent Expiry of some branded products.